previously demonstrated that the A242S mutation was located in a region critical for correct AR folding, and that this substitution could lead to a moderate conformational change of the AR TAD associated with MAIS and azoospermia. The A242S mutation is highly conserved between different species, and is adjacent to the V243G mutation identified in the present case (Figure 1h) . 4 Therefore, p.V243G may also affect the AR function, and this is supported by structural and functional analysis that showed the substitution changes a random coil into an extended strand, Dear Editor,
We present here a rare case that an infertile man had gynecomastia for 8 years, which might be caused by a novel mutation (c. 728 T > G) found in the transactivation domain (TAD) of androgen receptor (AR) gene.
The AR, an intracellular ligand-activated transcription factor, is encoded by a single-copy gene located on Xq11-q12. 1 This gene comprises eight exons, of which exon 1 codes for the N-terminal TAD, exons 2-3 encode the DNA-binding domain, and exons 4-8 encode a C-terminal hormone-binding domain.
2 AR mutations cause androgen insensitivity syndrome (AIS), which is characterized by a complete or partial resistance to androgen. This can be subdivided into three phenotypes: complete AIS with typical female external genitalia, partial AIS with predominantly female, predominantly male, or ambiguous external genitalia, and mild AIS (MAIS) with typical male external genitalia. Until date, more than 1000 AR mutations have been annotated in the AR gene mutation database (http://www.androgendb.mcgill. ca), with more than 100 clustered in exon 1. This report describes a novel missense mutation in the AR TAD in an infertile man with gynecomastia.
A 30-year-old infertile man who had gynecomastia for 8 years was admitted to the reproductive medicine center of our hospital (Figure 1a) . He was of medium height with a hairless face and no apparent Adam's apple. His penis was small, and the testes were palpable, but soft in texture. They were also decreased in size, with a testicular volume of 10 ml as measured by an orchidometer on each side (Figure 1b) . The epididymis and vas deferens were observed bilaterally. Pelvic magnetic resonance imaging (MRI) showed that the prostate was decreased in size (Figure 1c and 1d) . Routine karyotyping revealed a 46, XY karyotype, 21pstk + with two trabants. Semen analysis could not be done due to an ejaculation, even with orgasm and hence we An infertile man with gynecomastia caused by a novel mutation of the androgen receptor gene altering the secondary structure of the protein and slightly impairing the AR interaction with androgen. It is, therefore, possible that this mutation is responsible for testicular hypoplasia as seen in a report by Hose et al. 5 Because the levels of PRL, ACTH, GH, and TSH were all normal in the present case, it is likely that the pituitary microadenoma was nonfunctional. However, the lack of response to the GnRH test indicated that the mutation caused a dysfunction of androgen feedback in the hypothalamus and pituitary. 6 The observed elevated levels of LH are also likely to reflect the consequence of an impaired feedback regulation of T on LH secretion caused by AR dysfunction in the hypothalamic-pituitary axis. 6 Consistent with some reported studies, the concentration of T in our patient was within the normal range. 4, 7 FSH levels in AIS patients can also be variable, as FSH secretion is additionally controlled by inhibin B, which is a marker of spermatogenesis, originating from the Sertoli cells. 8 In MAIS patients, low levels of inhibin B cause increased FSH secretion, correlating with the Sertoli cell-only phenotype. 9 Moreover, the chromosome karyotype 46, XY, 21pstk + with two trabants is a common polymorphism that might not be related to the aberrant expression of hormones. 10 In summary, a novel mutation was identified in the AR TAD of an infertile male patient. This mutation could be responsible for various MAIS symptoms such as gynecomastia and impaired spermatogenesis. It will also enrich the AR database and lay the foundation for clinical diagnosis and therapy of affected patients.
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